CD4 and neoplasm: Intriguingly, this conclusion aligned with our findings from the EPIC analysis and CIBERSORT, strongly suggesting that the MPIGs-derived risk scores can distinguish between two tumor immune microenvironments characterized by different cell types, including CD4+ T cells, B cells, and macrophages.